Literature DB >> 9635850

Neuromuscular toxicities of paclitaxel 210 mg m(-2) by 3-hour infusion.

H Kunitoh1, N Saijo, K Furuse, K Noda, M Ogawa.   

Abstract

We retrospectively analysed neuromuscular toxicity associated with paclitaxel 210 mg m(-2) given by 3-h infusion in 247 patients. The severity correlated significantly with total cumulative dose, but could not be predicted by the pretreatment clinical variables or by pharmacokinetic parameters. The toxicity tended to occur in early treatment cycles.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9635850      PMCID： PMC2150075          DOI： 10.1038/bjc.1998.278

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  10 in total

Review 1.  Theoretical and practical aspects of paclitaxel scheduling.

Authors:  L Gianni
Journal:  Ann Oncol       Date:  1995-11       Impact factor: 32.976

2.  Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer.

Authors:  J H Schiller; B Storer; K Tutsch; R Arzoomanian; D Alberti; C Feierabend; D Spriggs
Journal:  J Clin Oncol       Date:  1994-02       Impact factor: 44.544

3.  Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma.

Authors:  P H Wiernik; E L Schwartz; A Einzig; J J Strauman; R B Lipton; J P Dutcher
Journal:  J Clin Oncol       Date:  1987-08       Impact factor: 44.544

4.  Paclitaxel-induced neuropathy.

Authors:  T J Postma; J B Vermorken; A J Liefting; H M Pinedo; J J Heimans
Journal:  Ann Oncol       Date:  1995-05       Impact factor: 32.976

5.  European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.

Authors:  E A Eisenhauer; W W ten Bokkel Huinink; K D Swenerton; L Gianni; J Myles; M E van der Burg; I Kerr; J B Vermorken; K Buser; N Colombo
Journal:  J Clin Oncol       Date:  1994-12       Impact factor: 44.544

6.  Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion.

Authors:  T Ohtsu; Y Sasaki; T Tamura; Y Miyata; H Nakanomyo; Y Nishiwaki; N Saijo
Journal:  Clin Cancer Res       Date:  1995-06       Impact factor: 12.531

7.  Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans.

Authors:  L Gianni; C M Kearns; A Giani; G Capri; L Viganó; A Lacatelli; G Bonadonna; M J Egorin
Journal:  J Clin Oncol       Date:  1995-01       Impact factor: 44.544

8.  Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies.

Authors:  V Chaudhry; E K Rowinsky; S E Sartorius; R C Donehower; D R Cornblath
Journal:  Ann Neurol       Date:  1994-03       Impact factor: 10.422

9.  Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities.

Authors:  T Tamura; Y Sasaki; Y Nishiwaki; N Saijo
Journal:  Jpn J Cancer Res       Date:  1995-12

10.  Phase I and pharmacokinetic study of paclitaxel by 24-hour intravenous infusion.

Authors:  T Tamura; Y Sasaki; K Eguchi; T Shinkai; Y Ohe; M Nishio; H Kunikane; H Arioka; A Karato; H Omatsu
Journal:  Jpn J Cancer Res       Date:  1994-10
  10 in total
  6 in total

1.  Abnormal muscle afferent function in a model of Taxol chemotherapy-induced painful neuropathy.

Authors:  Xiaojie Chen; Paul G Green; Jon D Levine
Journal:  J Neurophysiol       Date:  2011-05-11       Impact factor: 2.714

2.  Muscle pain in models of chemotherapy-induced and alcohol-induced peripheral neuropathy.

Authors:  Pedro Alvarez; Luiz F Ferrari; Jon D Levine
Journal:  Ann Neurol       Date:  2011-07       Impact factor: 10.422

3.  Second messengers mediating high-molecular-weight hyaluronan-induced antihyperalgesia in rats with chemotherapy-induced peripheral neuropathy.

Authors:  Ivan J M Bonet; Larissa Staurengo-Ferrari; Dionéia Araldi; Paul G Green; Jon D Levine
Journal:  Pain       Date:  2021-12-06       Impact factor: 7.926

4.  The challenge of preserving cardiorespiratory fitness in physically inactive patients with colon or breast cancer during adjuvant chemotherapy: a randomised feasibility study.

Authors:  Tom Møller; Christian Lillelund; Christina Andersen; Kira Bloomquist; Karl Bang Christensen; Bent Ejlertsen; Lone Nørgaard; Liza Wiedenbein; Peter Oturai; Ulla Breitenstein; Lis Adamsen
Journal:  BMJ Open Sport Exerc Med       Date:  2015-10-23

5.  Risk factor analysis for taxane-associated acute pain syndrome under the dexamethasone prophylaxis.

Authors:  Yoshitaka Saito; Yoh Takekuma; Masaki Kobayashi; Tatsuhiko Sakamoto; Hiroko Yamashita; Mitsuru Sugawara
Journal:  Support Care Cancer       Date:  2021-07-06       Impact factor: 3.603

6.  Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer.

Authors:  P A Vasey; R Atkinson; R Coleman; M Crawford; M Cruickshank; P Eggleton; D Fleming; J Graham; D Parkin; J Paul; N S Reed; S B Kaye
Journal:  Br J Cancer       Date:  2001-01       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.